​Astellas Partners with Kate Therapeutics in Gene Therapy, After Four Patient Deaths in Previous Trials

Thursday, Astellas Pharma announced its decision to license and advance a novel gene therapy from Kate Therapeutics for a debilitating muscle disorder. This move comes after four deaths and several severe adverse events occurred during clinical trials of a previous treatment from Astellas for the same condition.